Medicinova Inc (MNOV) Stock Price, Quote & News

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical my...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 373 1500

Fax: 858 404 0048

Website: medicinova.com

Address:

4275 Executive Square, Suite 300, La Jolla, United States

DARKP00L Mar. 16 at 11:36 AM

$MNOV 07:16 on Mar. 16 2026 HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10 #tradeideas

0 · Reply

BillionerOfKing Mar. 10 at 2:36 PM

$MNOV Current Stock Price: $1.40

0 · Reply

thepalace2007 Feb. 26 at 7:12 PM

$MNOV park a little cash here this could be $8+ with approval

0 · Reply

JudyBergmark348 Feb. 21 at 6:36 AM

$MNOV MediciNova develops small-molecule therapies for neurological and inflammatory diseases. Valuation is driven by clinical trial progress. Early-stage biotech risk remains elevated.

0 · Reply

thepalace2007 Feb. 19 at 5:19 PM

$MNOV earnings after hours

0 · Reply

CashDrifter Feb. 17 at 9:16 AM

$MNOV Pre-revenue biotech; early-stage

0 · Reply

OfficialStocktwitsUser Feb. 13 at 3:08 PM

$MNOV RSI: 10.00, MACD: 0.0142 Vol: 0.10, MA20: 1.68, MA50: 1.53 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Lionish Feb. 11 at 11:53 PM

$MNOV The company’s Chief Business Officer, David Crean, is interviewed on nano cap podcast episode 045. You can listen to it on YouTube.

0 · Reply

StreetwiseReports Feb. 2 at 6:44 PM

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market https://ow.ly/hEbB50Y7M7h Biopharmaceutical firm MediciNova Inc. ($MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year.

0 · Reply

StreetwiseReports Feb. 2 at 6:05 PM

Biopharma Reaches 50% Enrollment in New ALS Drug Program https://ow.ly/5yoQ50Y7KJB MediciNova Inc. ($MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.

0 · Reply